Literature DB >> 25550841

Uterine superficial serous carcinomas and extensive serous endometrial intraepithelial carcinomas: clinicopathological analysis of 6 patients.

Kyoko Ono1, Hiroyuki Hayashi2, Masatoshi Tateno3, Reiko Tanaka4, Rie Suzuki5, Yasuyo Maruyama6, Yohei Miyagi7, Mitsuko Furuya8.   

Abstract

Uterine superficial serous carcinoma (SSC) and serous endometrial intraepithelial carcinoma (SEIC) are unique malignancies found primarily in postmenopausal women. SSC and SEIC lesions measuring 1 cm or less are categorized as minimal uterine serous carcinoma (MUSC). Less well understood, however, the clinical behavior of SSC and SEIC lesions measuring more than 1 cm. We investigated 6 postmenopausal patients, aged 69-83 years, with SSC or SEIC and without hyperestrogenism. All but 1 patient had tumors originating from the surface of polyps, including 3 patients who each had an enormous polyp occupying the entire uterine cavity. Two patients had extensive SEICs measuring more than 1 cm; the others had SSCs, including 1 MUSC. The mesenchymal cells of the cancer-bearing polyps lacked the morphologic characteristics of endometrial stroma, and the cancer glands often immunostained negatively for estrogen receptors and progesterone receptors. Diffuse immunostaining for human epidermal growth factor receptor 2 was detected in 3 patients, and p53 was detected in all. Cyclin E, a downstream molecule of the F-box and WD repeat domain-containing 7 (FBXW7), was detected in all patients. Microdissected cancer glands showed p53 mutations in 2 patients and a FBXW7 mutation in 1 patient. These findings suggest that mutations of FBXW7 and p53 may contribute to the carcinogenesis of less invasive tumor subtypes. Pathologists and physicians should carefully evaluate SSC and SEIC lesions involving large polyps but lacking myometrial invasion.

Entities:  

Keywords:  F-box and WD repeat domain-containing 7 (FBXW7); Superficial uterine serous carcinoma; cyclin E; p53; polyp

Mesh:

Year:  2014        PMID: 25550841      PMCID: PMC4270535     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  17 in total

1.  p53 Mutation analysis in breast tumors by a DNA microarray method.

Authors:  Meredith Tennis; Shiva Krishnan; Matthew Bonner; Christine B Ambrosone; John E Vena; Kirsten Moysich; Helen Swede; Susan McCann; Per Hall; Peter G Shields; Jo L Freudenheim
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-01       Impact factor: 4.254

Review 2.  A proposed model for endometrial serous carcinogenesis.

Authors:  Wenxin Zheng; Li Xiang; Oluwole Fadare; Beihua Kong
Journal:  Am J Surg Pathol       Date:  2011-01       Impact factor: 6.394

3.  Minimal uterine serous carcinoma: diagnosis and clinicopathologic correlation.

Authors:  D T Wheeler; K A Bell; R J Kurman; M E Sherman
Journal:  Am J Surg Pathol       Date:  2000-06       Impact factor: 6.394

4.  Endometrial glandular dysplasia: a putative precursor lesion of uterine papillary serous carcinoma. Part II: molecular features.

Authors:  Sharon X Liang; Setsuko K Chambers; Liang Cheng; Shaopo Zhang; Yi Zhou; Wenxin Zheng
Journal:  Int J Surg Pathol       Date:  2004-10       Impact factor: 1.271

5.  Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma.

Authors:  Siming Zhao; Murim Choi; John D Overton; Stefania Bellone; Dana M Roque; Emiliano Cocco; Federica Guzzo; Diana P English; Joyce Varughese; Sara Gasparrini; Ileana Bortolomai; Natalia Buza; Pei Hui; Maysa Abu-Khalaf; Antonella Ravaggi; Eliana Bignotti; Elisabetta Bandiera; Chiara Romani; Paola Todeschini; Renata Tassi; Laura Zanotti; Luisa Carrara; Sergio Pecorelli; Dan-Arin Silasi; Elena Ratner; Masoud Azodi; Peter E Schwartz; Thomas J Rutherford; Amy L Stiegler; Shrikant Mane; Titus J Boggon; Joseph Schlessinger; Richard P Lifton; Alessandro D Santin
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-28       Impact factor: 11.205

6.  Endometrial glandular dysplasia with frequent p53 gene mutation: a genetic evidence supporting its precancer nature for endometrial serous carcinoma.

Authors:  Lin Jia; Yongjuan Liu; Xiaofang Yi; Alexander Miron; Christopher P Crum; Beihua Kong; Wenxin Zheng
Journal:  Clin Cancer Res       Date:  2008-03-27       Impact factor: 12.531

Review 7.  The Fbxw7/hCdc4 tumor suppressor in human cancer.

Authors:  YingMeei Tan; Olle Sangfelt; Charles Spruck
Journal:  Cancer Lett       Date:  2008-06-09       Impact factor: 8.679

8.  Loss of FBXW7, a cell cycle regulating gene, in colorectal cancer: clinical significance.

Authors:  Masaaki Iwatsuki; Koshi Mimori; Hideshi Ishii; Takehiko Yokobori; Yasushi Takatsuno; Tetsuya Sato; Hiroyuki Toh; Ichiro Onoyama; Keiichi I Nakayama; Hideo Baba; Masaki Mori
Journal:  Int J Cancer       Date:  2010-04-15       Impact factor: 7.396

9.  Significance of comprehensive surgical staging in noninvasive papillary serous carcinoma of the endometrium.

Authors:  John K Chan; Vera Loizzi; Mark Youssef; Kathryn Osann; Joanne Rutgers; Steven A Vasilev; Michael L Berman
Journal:  Gynecol Oncol       Date:  2003-07       Impact factor: 5.482

10.  Endometrial glandular dysplasia: a newly defined precursor lesion of uterine papillary serous carcinoma. Part I: morphologic features.

Authors:  Wenxin Zheng; Sharon X Liang; Herbert Yu; Thomas Rutherford; Setsuko K Chambers; Peter E Schwartz
Journal:  Int J Surg Pathol       Date:  2004-07       Impact factor: 1.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.